Research prototype, not medical advice.

Arimoclomol, which boosts the chaperone response, slows the progression of Niemann-Pick disease type C (phase 2/3); FDA-approved in 2024.

Confidence
Established
Level of evidence
Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisArimoclomolNiemann-Pick disease type CMolecular chaperones (HSP70, HSP90)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment
Mengel et al. · Journal of Inherited Metabolic Disease 2021
— Verified